Diagnostic Performance of Plasma SP-D, KL-6, and CC16 in Acutely Hospitalised Patients Suspected of Having Community-Acquired Pneumonia—A Diagnostic Accuracy Study
Authors:
- Anne HeltborgAHAnne Heltborg
- Christian B. MogensenCMChristian B. Mogensen
- Eline S. AndersenEAEline S. Andersen
- Mariana B. CartuliaresMCMariana B. Cartuliares
- Eva R. B. PetersenEPEva R. B. Petersen
- Thor A. SkovstedTSThor A. Skovsted
- Stefan PosthSPStefan Posth
- Ole GraumannOGOle Graumann
- Morten J. LorentzenMLMorten J. Lorentzen
- Mathias A. HertzMHMathias A. Hertz
- Claus L. BrasenCBClaus L. Brasen
- Helene Skjøt-ArkilHSHelene Skjøt-Arkil
Open Access
- 17 June 2024
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 14 (12) , 1283
Abstract
Community-acquired pneumonia is a common cause of acute hospitalisation. Identifying patients with community-acquired pneumonia among patients suspected of having the disease can be a challenge, which causes unnecessary antibiotic treatment. We investigated whether the circulatory pulmonary injury markers surfactant protein D (SP-D), Krebs von den Lungen-6 (KL-6), and Club cell protein 16 (CC16) could help identify patients with community-acquired pneumonia upon acute admission. In this multi-centre diagnostic accuracy study, SP-D, KL-6, and CC16 were quantified in plasma samples from acutely hospitalised patients with provisional diagnoses of community-acquired pneumonia. The area under the receiver operator characteristics curve (AUC) was calculated for each marker against the following outcomes: patients’ final diagnoses regarding community-acquired pneumonia assigned by an expert panel, and pneumonic findings on chest CTs. Plasma samples from 339 patients were analysed. The prevalence of community-acquired pneumonia was 63%. AUCs for each marker against both final diagnoses and chest CT diagnoses ranged between 0.50 and 0.56. Thus, SP-D, KL-6, and CC16 demonstrated poor diagnostic performance for community-acquired pneumonia in acutely hospitalised patients. Our findings indicate that the markers cannot readily assist physicians in confirming or ruling out community-acquired pneumonia.Keywords
Funding Information
- University of Southern Denmark (20/20 505, A583)
- Region of Southern Denmark (20/20 505, A583)
This publication has 31 references indexed in Scilit:
- Prognostic value of serum Krebs von den Lungen-6 (KL-6) levels in COVID-19 pneumoniaRespiratory Medicine and Research, 2023
- Serum Krebs von den Lungen-6 is associated with in-Hospital mortality of patients with severe Community-Acquired Pneumonia: A retrospective cohort studyClinica Chimica Acta, 2023
- Community-Acquired PneumoniaNew England Journal of Medicine, 2023
- Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analysesVirology, 2021
- The accuracy of a diagnosis of pneumonia in the emergency departmentInternational Journal of Infectious Diseases, 2019
- Emergency Medicine Evaluation of Community-Acquired Pneumonia: History, Examination, Imaging and Laboratory Assessment, and Risk ScoresThe Journal of Emergency Medicine, 2017
- Community-Acquired Pneumonia Requiring Hospitalization among U.S. AdultsNew England Journal of Medicine, 2015
- A multicenter analysis of the ED diagnosis of pneumoniaThe American Journal of Emergency Medicine, 2010
- Admission Chest Radiograph Lacks Sensitivity in the Diagnosis of Community-Acquired PneumoniaThe American Journal of the Medical Sciences, 2009
- Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumoniaClinical Immunology, 2003